Vectus Biosystems Limited (ASX: VBS)
Health Care · Biotechnology · AU
AU$0.16
+23.08% today · +92.8% 1Y
Vectus Biosystems Limited (ASX: VBS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $7.05M and employs 5 people.
Over the last twelve months the share price has gained 92.8%, trading between 0.05 and 0.46.
Tweenvest scores Vectus Biosystems Limited across four factors: quality 12/100, value 51/100, growth 0/100. Its strongest factor is value.
VBS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.05M
- Revenue (TTM)
- $60.01K
- P/E
- —
- EPS
- -0.03
- Dividend yield
- —
- Beta (5Y)
- 0.29
- 52-week high
- AU$0.46
- 52-week low
- AU$0.05
- Avg volume (3M)
- —
- Shares outstanding
- 61.49M
- Employees
- 5
- Next earnings
- —
About Vectus Biosystems Limited
Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
- ISIN
- AU000000VBS9
- Founded
- 2005
- Listed since
- Feb 22, 2016
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.89 | -4.26% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.